Selected research
Market Structure
Global Nano Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Nano Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Nano Antibodies include Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), Alphamab Oncology, Beroni Group, ChromoTek GmbH, Cusabio Technology LLC., DiosCURE Therapeutics SE, ExeVir Bio BV and Genscript, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Nano Antibodies market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Nano Antibodies and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Nano Antibodies revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Nano Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.
Nano Antibodies Segment by Company
Absolute Antibody
Alpalife (Shenzhen kangti Co., Ltd.)
Alphamab Oncology
Beroni Group
ChromoTek GmbH
Cusabio Technology LLC.
DiosCURE Therapeutics SE
ExeVir Bio BV
Genscript
PerkinElmer Inc. (BioLegend, Inc.)
Sensei Biotherapeutics, Inc.
Taisho Pharmaceutical Holdings
Merck KGaA
Novartis AG
Thermo Fisher Scientific Inc.
Sanofi (Ablynx)
Nano Antibodies Segment by Type
Fusion Nanobody
Multivalent and multispecific Nanobodies
Monovalent Nanobody
Nano Antibodies Segment by Application
Tumor targeted therapy
Circulatory disease
Disease detection in vitro
Non-invasive diagnosis in vivo
Nervous system disease
Infectious disease
Other
Nano Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nano Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Nano Antibodies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nano Antibodies industry.
Chapter 3: Detailed analysis of Nano Antibodies companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nano Antibodiesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fusion Nanobody
- Multivalent and multispecific Nanobodies
- Monovalent Nanobody
Applications
- Tumor targeted therapy
- Circulatory disease
- Disease detection in vitro
- Non-invasive diagnosis in vivo
- Nervous system disease
- Infectious disease
- Other
Companies covered
- Absolute Antibody
- Alpalife (Shenzhen kangti Co., Ltd.)
- Alphamab Oncology
- Beroni Group
- ChromoTek GmbH
- Cusabio Technology LLC.
- DiosCURE Therapeutics SE
- ExeVir Bio BV
- Genscript
- PerkinElmer Inc. (BioLegend, Inc.)
- Sensei Biotherapeutics, Inc.
- Taisho Pharmaceutical Holdings
- Merck KGaA
- Novartis AG
- Thermo Fisher Scientific Inc.
- Sanofi (Ablynx)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Nano Antibodies Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Fusion Nanobody
- 1.2.3 Multivalent and multispecific Nanobodies
- 1.2.4 Monovalent Nanobody
- 1.3 Market Analysis by Application
- 1.3.1 Global Nano Antibodies Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Tumor targeted therapy
- 1.3.3 Circulatory disease
- 1.3.4 Disease detection in vitro
- 1.3.5 Non-invasive diagnosis in vivo
- 1.3.6 Nervous system disease
- 1.3.7 Infectious disease
- 1.3.8 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Nano Antibodies Growth Trends by Region
- 1.5.1 Global Nano Antibodies Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Nano Antibodies Market Size by Region (2021-2026)
- 1.5.3 Nano Antibodies Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Nano Antibodies Market Dynamics
- 2.1 Nano Antibodies Industry Trends
- 2.2 Nano Antibodies Industry Drivers
- 2.3 Nano Antibodies Industry Opportunities and Challenges
- 2.4 Nano Antibodies Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Nano Antibodies Revenue by Company (2021-2026)
- 3.2 Global Nano Antibodies Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Nano Antibodies Key Company Head office and Area Served
- 3.4 Global Nano Antibodies Company, Product Type & Application
- 3.5 Global Nano Antibodies Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Nano Antibodies Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Nano Antibodies Players Market Share by Revenue in 2025
- 3.6.3 2025 Nano Antibodies Tier 1, Tier 2, and Tier 3
4 Nano Antibodies Market by Type
- 4.1 Global Nano Antibodies Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Nano Antibodies Market Size by Type (2021-2032)
- 4.3 Global Nano Antibodies Market Size Share by Type (2021-2032)
5 Nano Antibodies Market by Application
- 5.1 Global Nano Antibodies Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Nano Antibodies Market Size by Application (2021-2032)
- 5.3 Global Nano Antibodies Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Absolute Antibody
- 6.1.1 Absolute Antibody Company Information
- 6.1.2 Absolute Antibody Business Overview
- 6.1.3 Absolute Antibody Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Absolute Antibody Nano Antibodies Product Portfolio
- 6.1.5 Absolute Antibody Recent Developments
- 6.2 Alpalife (Shenzhen kangti Co., Ltd.)
- 6.2.1 Alpalife (Shenzhen kangti Co., Ltd.) Company Information
- 6.2.2 Alpalife (Shenzhen kangti Co., Ltd.) Business Overview
- 6.2.3 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product Portfolio
- 6.2.5 Alpalife (Shenzhen kangti Co., Ltd.) Recent Developments
- 6.3 Alphamab Oncology
- 6.3.1 Alphamab Oncology Company Information
- 6.3.2 Alphamab Oncology Business Overview
- 6.3.3 Alphamab Oncology Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Alphamab Oncology Nano Antibodies Product Portfolio
- 6.3.5 Alphamab Oncology Recent Developments
- 6.4 Beroni Group
- 6.4.1 Beroni Group Company Information
- 6.4.2 Beroni Group Business Overview
- 6.4.3 Beroni Group Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Beroni Group Nano Antibodies Product Portfolio
- 6.4.5 Beroni Group Recent Developments
- 6.5 ChromoTek GmbH
- 6.5.1 ChromoTek GmbH Company Information
- 6.5.2 ChromoTek GmbH Business Overview
- 6.5.3 ChromoTek GmbH Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 ChromoTek GmbH Nano Antibodies Product Portfolio
- 6.5.5 ChromoTek GmbH Recent Developments
- 6.6 Cusabio Technology LLC.
- 6.6.1 Cusabio Technology LLC. Company Information
- 6.6.2 Cusabio Technology LLC. Business Overview
- 6.6.3 Cusabio Technology LLC. Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Cusabio Technology LLC. Nano Antibodies Product Portfolio
- 6.6.5 Cusabio Technology LLC. Recent Developments
- 6.7 DiosCURE Therapeutics SE
- 6.7.1 DiosCURE Therapeutics SE Company Information
- 6.7.2 DiosCURE Therapeutics SE Business Overview
- 6.7.3 DiosCURE Therapeutics SE Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 DiosCURE Therapeutics SE Nano Antibodies Product Portfolio
- 6.7.5 DiosCURE Therapeutics SE Recent Developments
- 6.8 ExeVir Bio BV
- 6.8.1 ExeVir Bio BV Company Information
- 6.8.2 ExeVir Bio BV Business Overview
- 6.8.3 ExeVir Bio BV Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 ExeVir Bio BV Nano Antibodies Product Portfolio
- 6.8.5 ExeVir Bio BV Recent Developments
- 6.9 Genscript
- 6.9.1 Genscript Company Information
- 6.9.2 Genscript Business Overview
- 6.9.3 Genscript Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Genscript Nano Antibodies Product Portfolio
- 6.9.5 Genscript Recent Developments
- 6.10 PerkinElmer Inc. (BioLegend, Inc.)
- 6.10.1 PerkinElmer Inc. (BioLegend, Inc.) Company Information
- 6.10.2 PerkinElmer Inc. (BioLegend, Inc.) Business Overview
- 6.10.3 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product Portfolio
- 6.10.5 PerkinElmer Inc. (BioLegend, Inc.) Recent Developments
- 6.11 Sensei Biotherapeutics, Inc.
- 6.11.1 Sensei Biotherapeutics, Inc. Company Information
- 6.11.2 Sensei Biotherapeutics, Inc. Business Overview
- 6.11.3 Sensei Biotherapeutics, Inc. Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Sensei Biotherapeutics, Inc. Nano Antibodies Product Portfolio
- 6.11.5 Sensei Biotherapeutics, Inc. Recent Developments
- 6.12 Taisho Pharmaceutical Holdings
- 6.12.1 Taisho Pharmaceutical Holdings Company Information
- 6.12.2 Taisho Pharmaceutical Holdings Business Overview
- 6.12.3 Taisho Pharmaceutical Holdings Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Taisho Pharmaceutical Holdings Nano Antibodies Product Portfolio
- 6.12.5 Taisho Pharmaceutical Holdings Recent Developments
- 6.13 Merck KGaA
- 6.13.1 Merck KGaA Company Information
- 6.13.2 Merck KGaA Business Overview
- 6.13.3 Merck KGaA Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Merck KGaA Nano Antibodies Product Portfolio
- 6.13.5 Merck KGaA Recent Developments
- 6.14 Novartis AG
- 6.14.1 Novartis AG Company Information
- 6.14.2 Novartis AG Business Overview
- 6.14.3 Novartis AG Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Novartis AG Nano Antibodies Product Portfolio
- 6.14.5 Novartis AG Recent Developments
- 6.15 Thermo Fisher Scientific Inc.
- 6.15.1 Thermo Fisher Scientific Inc. Company Information
- 6.15.2 Thermo Fisher Scientific Inc. Business Overview
- 6.15.3 Thermo Fisher Scientific Inc. Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Thermo Fisher Scientific Inc. Nano Antibodies Product Portfolio
- 6.15.5 Thermo Fisher Scientific Inc. Recent Developments
- 6.16 Sanofi (Ablynx)
- 6.16.1 Sanofi (Ablynx) Company Information
- 6.16.2 Sanofi (Ablynx) Business Overview
- 6.16.3 Sanofi (Ablynx) Nano Antibodies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Sanofi (Ablynx) Nano Antibodies Product Portfolio
- 6.16.5 Sanofi (Ablynx) Recent Developments
7 North America
- 7.1 North America Nano Antibodies Market Size (2021-2032)
- 7.2 North America Nano Antibodies Market Size by Type
- 7.2.1 North America Nano Antibodies Market Size by Type (2021-2026)
- 7.2.2 North America Nano Antibodies Market Size by Type (2027-2032)
- 7.2.3 North America Nano Antibodies Market Share by Type (2021-2032)
- 7.3 North America Nano Antibodies Market Size by Application
- 7.3.1 North America Nano Antibodies Market Size by Application (2021-2026)
- 7.3.2 North America Nano Antibodies Market Size by Application (2027-2032)
- 7.3.3 North America Nano Antibodies Market Share by Application (2021-2032)
- 7.4 North America Nano Antibodies Market Size by Country
- 7.4.1 North America Nano Antibodies Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Nano Antibodies Market Size by Country (2021-2026)
- 7.4.3 North America Nano Antibodies Market Size by Country (2027-2032)
- 7.4.4 North America Nano Antibodies Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Nano Antibodies Market Size (2021-2032)
- 8.2 Europe Nano Antibodies Market Size by Type
- 8.2.1 Europe Nano Antibodies Market Size by Type (2021-2026)
- 8.2.2 Europe Nano Antibodies Market Size by Type (2027-2032)
- 8.2.3 Europe Nano Antibodies Market Share by Type (2021-2032)
- 8.3 Europe Nano Antibodies Market Size by Application
- 8.3.1 Europe Nano Antibodies Market Size by Application (2021-2026)
- 8.3.2 Europe Nano Antibodies Market Size by Application (2027-2032)
- 8.3.3 Europe Nano Antibodies Market Share by Application (2021-2032)
- 8.4 Europe Nano Antibodies Market Size by Country
- 8.4.1 Europe Nano Antibodies Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Nano Antibodies Market Size by Country (2021-2026)
- 8.4.3 Europe Nano Antibodies Market Size by Country (2027-2032)
- 8.4.4 Europe Nano Antibodies Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Nano Antibodies Market Size (2021-2032)
- 9.2 China Nano Antibodies Market Size by Type
- 9.2.1 China Nano Antibodies Market Size by Type (2021-2026)
- 9.2.2 China Nano Antibodies Market Size by Type (2027-2032)
- 9.2.3 China Nano Antibodies Market Share by Type (2021-2032)
- 9.3 China Nano Antibodies Market Size by Application
- 9.3.1 China Nano Antibodies Market Size by Application (2021-2026)
- 9.3.2 China Nano Antibodies Market Size by Application (2027-2032)
- 9.3.3 China Nano Antibodies Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Nano Antibodies Market Size (2021-2032)
- 10.2 Asia Nano Antibodies Market Size by Type
- 10.2.1 Asia Nano Antibodies Market Size by Type (2021-2026)
- 10.2.2 Asia Nano Antibodies Market Size by Type (2027-2032)
- 10.2.3 Asia Nano Antibodies Market Share by Type (2021-2032)
- 10.3 Asia Nano Antibodies Market Size by Application
- 10.3.1 Asia Nano Antibodies Market Size by Application (2021-2026)
- 10.3.2 Asia Nano Antibodies Market Size by Application (2027-2032)
- 10.3.3 Asia Nano Antibodies Market Share by Application (2021-2032)
- 10.4 Asia Nano Antibodies Market Size by Country
- 10.4.1 Asia Nano Antibodies Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Nano Antibodies Market Size by Country (2021-2026)
- 10.4.3 Asia Nano Antibodies Market Size by Country (2027-2032)
- 10.4.4 Asia Nano Antibodies Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Nano Antibodies Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Nano Antibodies Market Size by Type
- 11.2.1 South America, Middle East & Africa Nano Antibodies Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Nano Antibodies Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Nano Antibodies Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Nano Antibodies Market Size by Application
- 11.3.1 South America, Middle East & Africa Nano Antibodies Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Nano Antibodies Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Nano Antibodies Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Nano Antibodies Market Size by Country
- 11.4.1 South America, Middle East & Africa Nano Antibodies Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Nano Antibodies Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Nano Antibodies Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Nano Antibodies Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst